KR890002185A - Novel Cefem Compounds and Their Uses - Google Patents

Abstract

No content

Description

Novel Cefem Compounds and Their Uses

Since this is an open matter, no full text was included.

Claims (15)

A compound of formula (I) or a pharmacologically acceptable salt thereof. Wherein Q is nitrogen or CH; R ¹ is hydrogen or lower alkyl which may be substituted; Ring A has a ring-forming carbon atom of the general formula: -E- (CH ₂ ) nR ² , wherein E is sulfur or NH; R ² is amino, carbamoylamino, formylamino, acetylamino, N- Pyridine or pyridazine ring substituted by a group of formimidoylamino, N-acetimidoylamino, lower alkylamino, hydroxyl or carbamoyl oxy group; n is an integer from 2 to 4). 2. A pyridazine ring according to claim 1, wherein ring A is substituted with a group whose ring-constituting carbon atom is substituted by a group of the formula: -S- (CH ₂ ) nR ² , wherein the symbol is as defined in claim 1. A compound or a pharmacologically acceptable salt thereof. 2. A ring according to claim 1, wherein ring A is a pyridine ring whose ring-constituting carbon atom is substituted by a group of the formula: -S- (CH ₂ ) nR ² , wherein the symbol is as defined in claim 1. Characterized in the compound or a pharmacologically acceptable salt thereof. A compound according to claim 1, or a pharmacologically acceptable salt thereof, wherein E is NH. The compound according to claim 2, or a pharmacologically acceptable salt thereof, wherein R ² is a formylamino or carbamoyloxy group. 4. A compound according to claim 3, or a pharmacologically acceptable salt thereof, wherein R ² is a formylamino or carbamoyloxy group. The compound or pharmacologically acceptable salt thereof according to claim 4, wherein R ² is a formylamino or carbamoyloxy group. A compound according to claim ₁ or a pharmacologically acceptable salt thereof, wherein R ¹ is a C _1-6 alkyl group which may be substituted by either an amino or vinyl group. The compound of claim 3, wherein the compound is 7β- [2- (2-aminothiazol-4-yl)-(Z) -2-ethoxyimino acetamido] -3-[[5- (2-amino ethyl Thio) imidazo [1,2-a] pyridinium-1-yl] methyl] -3-cepem-4-carboxylate or a pharmacologically acceptable salt thereof, or a pharmacologically acceptable salt thereof salt. The compound of claim 4, wherein the compound is 7β- [2- (2-aminothiazol-4-yl)-(Z) -2-ethoxyimino acetamido] -3-[[5- (2-amino ethyl Thio) imidazo [1,2-b] pyridazinium-1-yl] methyl] -3-cepem-4-carboxylate or a pharmacologically acceptable salt thereof, or a pharmacologically acceptable thereof Salt. The compound of claim 2, wherein the compound is 7β- [2- (2-aminothiazol-4-yl)-(Z) -2-ethoxyimino acetamido] -3-[[5- (2-amino ethyl Thio) imidazo [1,2-b] pyridazinium-1-yl] methyl] -3-cepem-4-carboxylate or a pharmacologically acceptable salt thereof, or a pharmacologically acceptable thereof Salt. The compound of claim 3, wherein the compound is 7β- [2- (2-aminothiazol-4-yl)-(Z) -2-ethoxyimino acetamido] -3-[[5- (2-carba Moyloxyethylthio) imidazo [1,2-a] pyridinium-1-yl] methyl] -3-cepem-4-carboxylate or a pharmacologically acceptable salt thereof, or a pharmacological agent thereof Acceptable salts. The compound of claim 3, wherein the compound is 7β- [2- (2-aminothiazol-4-yl)-(Z) -2-ethoxyimino acetamido] -3-[[5- (2-formyl Amino ethylthio) imidazo [1,2-a] pyridinium-1-yl] methyl] -3-cepem-4-carboxylate or a pharmacologically acceptable salt thereof or pharmacologically Acceptable salts. No content A pharmaceutical composition characterized by containing at least one of the following general formula (I) or a pharmacologically acceptable salt thereof. Wherein Q is nitrogen or CH; R ¹ is hydrogen or lower alkyl which may be substituted; Ring A has a ring-forming carbon atom of the general formula: -E- (CH ₂ ) nR ² , wherein E is sulfur or NH; R ² is amino, carbamoylamino, formylamino, acetylamino, N- Pyridine or pyridazine ring substituted by a group of formimidoylamino, N-acetimidoylamino, lower alkylamino, hydroxyl or carbamoyl oxy group; n is an integer from 2 to 4). ※ Note: The disclosure is based on the initial application.